NCT04909164Completed
The Prospective Non-randomized Case-control Study From Real-world Lung Cancer Patients
The Pragmatic Clinical Trial to Elucidate Optimal Target Population of Immunotherapy From Real-world Lung Cancer Patients
Source: ClinicalTrials.gov · Last updated 4 Sept 2026
Brief summary (registry, in English)
The pragmatic clinical trial to elucidate optimal target population of immunotherapy from real-world lung cancer patients
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1519 (actual)
- First submitted
- 26 May 2021
- Start date
- 15 Jun 2021
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Myung-Ju Ahn
- Diseases
- Lung cancer
- NCT number
- NCT04909164
What you commit to
- Study type: Observational
- Participants enrolled: 1519
- From 15 Jun 2021 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- 7-1 Inclusion criteria 7-1-1 Immunotherapy arm (prospective data collection)
- Male and female patients aged 19 years and above
- Patients with histologically confirmed NSCLC
- Patients on palliative therapy for recurrence after surgery or de novo advanced and metastatic disease
- Patients receiving reimbursed immunotherapy as second-line therapy (in case of targeted therapy, patients receiving immunotherapy after targeted therapy-platinum-based chemotherapy) or as reimbursed first-line therapy
- Patients who provided written informed consent for the study (including the secondary use of the study data and sharing with third parties) 7-1-2 Cytotoxic chemotherapy arm (prospective/retrospective data collection)
- Male and female patients aged 19 years and above
- Patients with histologically confirmed NSCLC
- Patients on palliative therapy for recurrence after surgery or de novo advanced and metastatic disease
- Prospective: Patients receiving reimbursed cytotoxic chemotherapy as second-line therapy after failure of platinum-based chemotherapy
- Retrospective: In addition to the prospective data, retrospective data will be collected from medical records of 680 patients (or more) who had records of receiving cytotoxic chemotherapy between January 1, 2017, and December 31, 2018 (1:1 comparison between the immunotherapy arm and the chemotherapy arm). If the patient did not die within the first 12 months after diagnosis, available follow-up data of at least 12 months will be collected from the medical records of the participating institution.Patients who provided written informed consent for the study (including the secondary use of the study data and sharing with third parties) 7-2 Exclusion criteria 7-2-1 Immunochemotherapy arm
- Patients receiving immunotherapy without reimbursement
- Patients who do not provide consent to the study 7-2-2 Cytotoxic chemotherapy arm
- Patients receiving cytotoxic chemotherapy without reimbursement
- Patients who do not provide consent to the study
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
Related publications
- Early On-Treatment Host Fitness Dynamics Refine Prognostic Stratification in Advanced NSCLC Receiving First-Line Immunotherapy.Cancer Res Treat · 2026 · PMID 42594970
This page is information, not medical advice. Discuss any trial with your doctor.